Dynacure SAS

Public biotech stocks are suffering after the excesses of 2020 and 2021. Some see a welcome correction, others an indiscriminate blood bath. Biotech’s coffers are stuffed with cash, cushioning the imp

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. CJ CheilJedang Acquires Batavia To Expa

Venture capital fundraising by biopharmaceutical companies totaled $5.7bn during the first quarter of 2020 – the second-highest amount ever raised by the industry in a single quarter – as private drug

Just four years after inception, the France/US rare diseases start-up Dynacure SAS has raised €50m ($55m) in a series C funding to help support an ongoing Phase I/II trial of its lead antisense cand